Physician profile
Phillip E Milam
NPI 1376525741
$2,539.66
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $856 · 2021: $501 · 2024: $97.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $97.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $97.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $427.48 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $382.86 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $310.82 | 2020-2021 | |
| Glaxosmithkline, LLC. | $269.97 | 2019-2024 | Arexvy |
| Lilly USA, LLC | $266.03 | 2019-2021 | |
| Allergan, INC. | $196.72 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $126.76 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.15 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $88.35 | 2019-2020 | |
| Assertio Therapeutics, INC. | $75.72 | 2019 | |
| Novo Nordisk INC | $62.69 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $52.21 | 2019-2020 | |
| Eisai INC. | $47.49 | 2020-2021 | |
| Genzyme Corporation | $24.72 | 2020 | |
| Boston Scientific Corporation | $23.55 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $18.79 | 2020 | |
| Acorda Therapeutics, INC | $16.72 | 2020 | |
| Amgen INC. | $15.96 | 2019 | |
| Adlon Therapeutics L.P. | $12.53 | 2020 | |
| Almatica Pharma LLC | $12.08 | 2021 | |
| Strongbridge US INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Milam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.